tiprankstipranks
Trending News
More News >
ProKidney (PROK)
NASDAQ:PROK
US Market
Advertisement

ProKidney (PROK) AI Stock Analysis

Compare
343 Followers

Top Page

PROK

ProKidney

(NASDAQ:PROK)

Select Model
Select Model
Select Model
Underperform 29 (OpenAI - 4o)
Rating:29Underperform
Price Target:
ProKidney's stock score is significantly impacted by its poor financial performance, characterized by weak revenue growth, high operational costs, and negative cash flow. The technical analysis suggests a bearish trend with mixed indicators, while the valuation reflects high volatility and risk due to negative earnings. Overall, the financial instability and operational challenges are the primary concerns, leading to a low stock score.
Positive Factors
Innovative Product
ProKidney's focus on innovative cellular therapies like REACT positions it at the forefront of CKD treatment, potentially transforming patient care and offering a competitive edge in the biotechnology sector.
Strategic Partnerships
Potential partnerships with larger pharmaceutical companies could enhance ProKidney's distribution capabilities, providing access to broader markets and additional revenue streams through upfront payments, milestones, and royalties.
Market Position
ProKidney's dedication to pioneering therapies for CKD positions it as a leader in a niche market, potentially capturing significant market share as demand for advanced kidney treatments grows.
Negative Factors
Weak Financial Performance
Persistent financial weaknesses, including lack of revenue growth and high costs, threaten ProKidney's long-term viability, limiting its ability to invest in R&D and expand operations.
High Leverage
High leverage and negative equity raise concerns about ProKidney's solvency, potentially restricting its financial flexibility and ability to withstand economic downturns or fund future growth.
Cash Flow Issues
Ongoing negative cash flow highlights inefficiencies in cash management, posing a risk to ProKidney's operational sustainability and ability to finance its strategic initiatives without external funding.

ProKidney (PROK) vs. SPDR S&P 500 ETF (SPY)

ProKidney Business Overview & Revenue Model

Company DescriptionProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
How the Company Makes MoneyProKidney makes money primarily through the development and commercialization of its innovative cellular therapies for chronic kidney disease, particularly through its flagship product, Renal Autologous Cell Therapy (REACT). The company seeks to generate revenue by advancing this product through clinical trials and achieving regulatory approval, which would allow it to market the therapy to healthcare providers and hospitals. Additionally, ProKidney may enter into partnerships or licensing agreements with larger pharmaceutical companies to enhance distribution capabilities and expand market reach, which could provide upfront payments, milestone payments, and royalties as key revenue streams.

ProKidney Financial Statement Overview

Summary
ProKidney's financial performance is severely weak with no revenue growth, high operational costs, and consistent negative profitability metrics. The balance sheet shows significant weaknesses with negative equity and high leverage, raising solvency concerns. Cash flow analysis indicates ongoing cash burn and inefficiencies, reflecting critical deficiencies in profitability and cash management.
Income Statement
10
Very Negative
ProKidney demonstrates weak financial performance with no revenue growth and consistent negative profitability metrics. Despite a minor revenue introduction in 2024, the company has maintained negative gross and net profit margins, indicating ongoing operational challenges. The EBIT and EBITDA margins remain deeply negative, underscoring the company's struggle to cover its operating costs.
Balance Sheet
15
Very Negative
The balance sheet shows significant weaknesses with negative stockholders' equity and high leverage. The debt-to-equity ratio is not meaningful due to negative equity, suggesting financial instability. Assets are largely covered by liabilities, and the equity ratio indicates a deficiency in equity financing. These factors highlight a precarious financial position, raising concerns about long-term solvency.
Cash Flow
20
Very Negative
Cash flow analysis shows persistent negative free cash flow and operating cash flow, indicating ongoing cash burn. The operating cash flow to net income ratio is negative, reflecting inefficiencies in converting net income to cash. Despite positive financing efforts, cash management remains a critical issue, as evidenced by negative free cash flow to net income ratio.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue527.00K76.00K0.000.000.000.00
Gross Profit527.00K76.00K-3.17M-3.04M-1.98M0.00
EBITDA-157.52M-158.49M-147.67M-143.99M-53.13M-26.02M
Net Income-72.47M-61.19M-35.47M-108.03M-55.15M-26.75M
Balance Sheet
Total Assets372.13M441.07M420.55M518.00M40.30M16.70M
Cash, Cash Equivalents and Short-Term Investments294.73M358.29M362.95M490.25M20.56M4.58M
Total Debt3.52M3.24M4.41M2.40M1.33M1.56M
Total Liabilities32.68M39.44M29.22M13.06M13.38M6.84M
Stockholders Equity339.45M-994.95M-1.10B-1.10B26.92M9.86M
Cash Flow
Free Cash Flow-172.67M-155.86M-124.27M-78.94M-55.49M-30.64M
Operating Cash Flow-143.62M-126.35M-90.07M-77.09M-50.30M-25.18M
Investing Cash Flow8.59M20.41M-329.98M-1.74M-5.19M-5.46M
Financing Cash Flow4.54M144.41M-9.55M548.52M71.47M19.99M

ProKidney Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.48
Price Trends
50DMA
2.61
Negative
100DMA
1.97
Positive
200DMA
1.63
Positive
Market Momentum
MACD
0.04
Positive
RSI
48.26
Neutral
STOCH
22.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PROK, the sentiment is Neutral. The current price of 2.48 is below the 20-day moving average (MA) of 2.50, below the 50-day MA of 2.61, and above the 200-day MA of 1.63, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 48.26 is Neutral, neither overbought nor oversold. The STOCH value of 22.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PROK.

ProKidney Risk Analysis

ProKidney disclosed 92 risk factors in its most recent earnings report. ProKidney reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ProKidney Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
$250.72M-2.44-44.25%-70.38%-683.06%
50
Neutral
$183.09M-4.202.18%-44.94%-274.42%
47
Neutral
$137.04M-2.35-17.89%3.93%
47
Neutral
$374.15M-5.87-24.60%
36
Underperform
$123.12M-0.7097.61%
29
Underperform
$729.82M4.66%4.97%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PROK
ProKidney
2.48
0.78
45.88%
RZLT
Rezolute
9.29
4.70
102.40%
URGN
Urogen Pharma
19.14
6.66
53.37%
PHAT
Phathom Pharmaceuticals
11.33
-5.65
-33.27%
RLAY
Relay Therapeutics
5.19
-1.36
-20.76%
NRIX
Nurix Therapeutics
9.28
-12.81
-57.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 01, 2025